This is the first cost-effectiveness analysis of the agent compared with the current standard of care using a constructed population-based control arm.
The dual PI3K/mTOR inhibitor LY3023414 also displayed moderate single-agent activity in this study of patients with heavily pretreated advanced endometrial cancer.
Researchers noted that these findings do not indicate that insurance alone will eliminate racial and ethnic disparities in breast cancer; however, it is one systemic change that may ameliorate consistent disparities.
The device allows plastic surgeons and other supervised specialists to ensure consistently superior, realistic, and customizable results for nipple-areola complex tattooing.
This research indicated that routine HPV testing may be necessary for patients with squamous cell carcinoma.
Researchers have yet to determine the optimal use of the AI system, though assessments in the clinical setting indicated that the technology could enhance screening results, potentially identifying breast cancer earlier than the standard of care.
The FDA granted accelerated approval of tazemetostat (Tazverik) based on data reported in a phase II clinical trial of the methyltransferase inhibitor.
This technology identified a practical method for detecting multiple gastrointestinal cancers from a single noninvasive blood test.
Given the data presented in this abstract, researchers indicated that it is crucial that further research works toward eliminating these disparities.
The patients with BRAF V600E-mutant metastatic colorectal cancer whose disease had progressed after 1 or 2 prior regimens reported substantial improvements in quality of life over the current standard of care.